Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

CD47 is an antiphagocytic molecule that contributes to tumor cell resistance in host immune surveillance. CD47 overexpression correlated with tumor progression and shorter survival in lung cancer. However, the expression and functional significance of CD47 in Non‐Small Cell Lung Cancer (NSCLC) has not been completely understood.

[1]  Xiaodong Yang,et al.  Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades , 2019, Cancer management and research.

[2]  D M Parkin,et al.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods , 2018, International journal of cancer.

[3]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Cardona,et al.  Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients , 2018, Oncotarget.

[5]  J. Zhao,et al.  Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage IIIa non-small cell lung cancer. , 2018 .

[6]  Huijun Zhao,et al.  Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis , 2018, Translational Cancer Research.

[7]  B. Tong,et al.  CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. , 2018, Future oncology.

[8]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[9]  Yun Yang,et al.  A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index , 2018, Biotechnology Letters.

[10]  Chun-lin Zhao,et al.  Characterization of cluster of differentiation 47 expression and its potential as a therapeutic target in esophageal squamous cell cancer. , 2017, Oncology letters.

[11]  O. Arrieta,et al.  CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients , 2017, British Journal of Cancer.

[12]  Lin F. Yang,et al.  Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells , 2017, Front. Immunol..

[13]  Steven E. Schild,et al.  Non-small cell lung cancer, version 5.2017: Clinical practice guidelines in oncology , 2017 .

[14]  Y. Okuno,et al.  Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer , 2017, Nature Communications.

[15]  S. Horrigan,et al.  Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2017, eLife.

[16]  K. Azuma,et al.  Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment , 2016, Front. Pharmacol..

[17]  J. Gu,et al.  N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4 , 2016, Scientific Reports.

[18]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[19]  A. Hidalgo-Miranda,et al.  Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure , 2016, Respiratory Research.

[20]  D. Felsher,et al.  MYC regulates the antitumor immune response through CD47 and PD-L1 , 2016, Science.

[21]  Daoud M. Meerzaman,et al.  A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer , 2016, Oncotarget.

[22]  J. Taube,et al.  Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. , 2016, Cancer research.

[23]  A. Azmi,et al.  Immune evasion in cancer: Mechanistic basis and therapeutic strategies. , 2015, Seminars in cancer biology.

[24]  Y. Huang,et al.  Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Y. Nakanishi,et al.  Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Yuan Zhang,et al.  Crosstalk between colon cancer cells and macrophages via inflammatory mediators and CD47 promotes tumour cell migration. , 2013, European journal of cancer.

[27]  C. Migliaccio,et al.  Adverse effects of wood smoke PM2.5 exposure on macrophage functions , 2013, Inhalation toxicology.

[28]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[29]  I. Weissman,et al.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. , 2011, Blood.

[30]  K. O'Byrne,et al.  Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. , 2011, The Lancet. Oncology.

[31]  D. Roberts,et al.  Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47* , 2010, The Journal of Biological Chemistry.

[32]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[33]  D. Rimm,et al.  X-Tile , 2004, Clinical Cancer Research.

[34]  B. Taylor,et al.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. , 2017, Cancer discovery.

[35]  B. Seliger.  Strategies of Tumor Immune Evasion , 2012, BioDrugs.

[36]  K. O'Byrne,et al.  EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. , 2012, The Lancet. Oncology.